Stock Symbol PHMB.PK
Recent Price $0.003
Intermediate Target Price $0.016
PharmaCom BioVet, Inc. is in the business of providing integrated animal healthcare services utilizing veterinary oncology, or the study and treatment of cancer in companion animals. In the United States alone, it is estimated that companion animal caregivers spend in excess of $52 billion annually on overall companion animal care. It is also estimated that over $17 billion annually (2006) is spent on veterinary care. PharmaCom BioVet has developed a comprehensive business plan to accelerate product research and development. Additionally, the company intends to introduce a series of proprietary devices and compounds that will enable animals suffering form cancer greater life expectancy and decreased suffering.
PHARMACOM BIOVET, INC.
(PHMB.PK)
BUSINESS STRATEGY
- PharmaCom BioVet is committed to increasing shareholder value, aggressively pursuing strategic alliances that can add immediately to the product line.
- Securing funding to properly manage the company’s planned growth
- Implementing comprehensive marketing plans and realistic revenue projections
- Capitalizing on the growing veterinary market, as there have been few other viable cancer therapeutic products introduced into the veterinary marketplace over the past 30 years
- Expanding the number of affiliated sites to increase its revenue base and help meet operating expenses
As animal lovers, there is nothing you wouldn’t do for your pet. Cancer in pets has been on the rise the past few years. For dogs over six years of age, 60 percent will be diagnosed with some form of cancer. Nearly half the deaths of pets more than 10 years old are from cancer. There are nearly 100 types of animal cancer. The most common type is leukemia, and the most common cancer for dogs is lymphoma and mammary gland cancer. Because of treatment advances PharmaCom BioVet offers, pets with cancer have a much better chance of survival then they did just a few short years ago.
PHMB remains dedicated to advancing the medical care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the United States and beyond. The company has a top-notch, highly skilled and well-respected management team leading its Board of Directors and operations division.
FUTURE PLANS
PharmaCom BioVet has begun to establish facilities for the treatment and further development of Veterinary Oncology Canine Cancer Treatment Centers in Missouri, Texas and Connecticut. The expansion of these sites should allow the company to provide more comprehensive services, thereby increasing the revenue earned from each. The expansion of owned and affiliated sites will create further market outlets for the company’s treatment services and allow greater market capture of the underlying populations requiring those services. The expanded network will be positioned to capture canine heath services as a managed care disease-specific provider, providing larger economies of scale, allowing more clinical data for medical and financial analysis, and likely, allowing PHMB to conduct larger clinical trials of its Bone Marrow Transplant technique. Of note, there are in excess of over 10,000 dogs annually in the U. S. receiving chemotherapy for lymphoma cancer alone, with a life expectancy, of up to 1 year, on average.
These are the target patients of PharmaCom BioVet, Inc. Through this treatment, the company hopes to improve the prognosis for life expectancy --- 3 to 5 times longer from what is currently being seen.
INVESTMENT CONSIDERATIONS
There are exciting and challenging opportunities in areas of bone marrow transplant and other cancer treatment technologies for companion animals. Products developed by bright and enterprising engineers, medical professionals and others, are ready for the final stages of registration. PharmaCom BioVet, Inc. is well positioned to use its capital and management skills to evaluate new ventures, as well as implement plans for current ventures, and operate its new centers to achieve sales and revenue growth. At this current level, PHMB represents a most compelling investment opportunity for those investors who aggressively seek the potential of maximum long-term capital gains in a dynamically growing entity. The company is now poised for dramatic and profitable growth. It is PHMB’s objective to capitalize on the relationships and partnerships with some of the top Veterinary Oncologists and Veterinary Researchers in the U.S. to enable management to bring revolutionary new treatment procedures to the companion animal healthcare market.
Management states, “The development and commercial availability of a new veterinary-specific cancer treatment suggests the potential for high profitability, based upon known and projected demand. These profits would not only support a strong revenue stream for PharmaCom BioVet, Inc.’s operations, but would also allow for the ongoing development of further products and/or treatment techniques.”
ANALYST
Officers of Market Advisors, Inc. have been in business since 1983 and have provided stock market research for their clients since 1985. Company officials have often been quoted in a wide array of financial publications such as the Wall Street Journal, Investors Business Daily, Barron’s, Forbes Magazine and The Dick Davis Digest to name a few.
